BOSTON, MA, Expansion Therapeutics, a biotechnology company, has closed an $80 million Series B financing led by Cormorant Asset Management.
Expansion Therapeutics, a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases, has closed an $80 million Series B financing.
Cormorant Asset Management led the financing with participation from new investors Westlake Village BioPartners, Surveyor Capital (a Citadel company) and Logos Capital as well as Series A investors RA Capital Management, 5AM Ventures, Kleiner Perkins, Sanofi Ventures and Novartis Venture Fund.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
